Reports are emerging about the outlook for the bio/pharma industry in 2026, with some indicating a dynamic landscape that may be ripe for mergers and acquisitions, as well as cross-border partnerships. The year ahead is also expected to feature notable clinical trials and potentially increased activity in terms of fundraising. Overall sentiment appears to be positive, with some industry leaders expressing optimism about the prospects for 2026.